Unknown

Dataset Information

0

Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma.


ABSTRACT: A novel treatment strategy by co-targeting c-Myc and tumor stroma was explored in vemurafenib-resistant melanoma. BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated nanoliposomes (ARNIPL) were developed to incorporate a synergistic cytotoxic ratio. Both the molecules have extremely poor aqueous solubility. A modified hydration method with citric acid was used to improve the loading of both the molecules in liposomes. ARNIPL with mean particle size 111.1 ± 6.55 nm exhibited more than 90% encapsulation efficiency for both the drugs and was found to be physically stable for a month at 4 °C. Both the molecules and ARNIPL showed significantly higher cytotoxicity, apoptosis and down-regulation of target proteins BRD4 and c-Myc in vemurafenib-resistant cell line (A375R). Vasculogenic mimicry and clonogenic potential of A375R were significantly inhibited by ARNIPL. Tumor growth inhibition in 3D spheroids with reduction of TGF-β1 was observed with ARNIPL treatment. Therefore, ARNIPL could be a promising therapeutic approach for the treatment of vemurafenib-resistant melanoma.

SUBMITTER: Fu Y 

PROVIDER: S-EPMC8308940 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6611856 | biostudies-other
| S-EPMC7093165 | biostudies-literature
| S-EPMC8224805 | biostudies-literature
| S-EPMC10341710 | biostudies-literature
| S-EPMC6844026 | biostudies-literature
| S-EPMC8061034 | biostudies-literature
| S-EPMC9224699 | biostudies-literature
| S-EPMC8559897 | biostudies-literature
| S-EPMC6095017 | biostudies-literature
| S-EPMC7398872 | biostudies-literature